Reference

difficult, and similarly, individual patient use and formulary decisions for Drug and Therapeutics Committees may be challenging. Key to good decision making is understanding the evidence before us, and distinguishing subtle marketing messages from clinical trial methodological details that form the scientific basis of good clinical practice